Literature DB >> 16753365

Prognostic significance of bladder tumor history and tumor location in upper tract transitional cell carcinoma.

Bulent Akdogan1, Hasan Serkan Dogan, Saadettin Yilmaz Eskicorapci, Ahmet Sahin, Ilhan Erkan, Haluk Ozen.   

Abstract

PURPOSE: We studied prognostic factors for 5-year disease specific and recurrence-free survival in patients treated for upper urinary tract transitional cell carcinoma.
MATERIALS AND METHODS: Since July 1987, 72 patients with a mean age of 58.9 years have undergone nephroureterectomy with bladder cuff excision. Median followup was 62.2 months (range 6 to 192). Patient age, sex, detection duration and mode, bladder tumor history, smoking habit, stone disease history, and tumor stage, grade and location were evaluated as prognostic factors.
RESULTS: Overall 5-year disease specific and recurrence-free survival rates were 74.9% and 67.8%, respectively. Univariate analysis revealed anemia, positive bladder tumor history, T stage, grade and tumor location in the upper tract as significant prognostic factors. On multivariate analysis T stage, grade and tumor location in the urothelium were the only significant variables for the 5-year disease specific and recurrence-free survival rates.
CONCLUSIONS: High tumor stage and grade, and ureteral location were significantly associated with worse disease specific and recurrence-free survival in patients with upper urinary tract transitional cell carcinoma. Our results may help define the patient groups that need adjuvant therapy and they may form a basis for further controlled studies.

Entities:  

Mesh:

Year:  2006        PMID: 16753365     DOI: 10.1016/S0022-5347(06)00511-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  32 in total

1.  Muscle-invasive bladder and urethral cancer recurrence after surgical management of upper tract urothelial carcinoma: A review of 305 patients.

Authors:  Mohamed Mohamed Elawdy; Yasser Osman; Diaa Eldin Taha; Samer El-Halwagy
Journal:  Turk J Urol       Date:  2018-03-06

2.  Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?

Authors:  Hanan Goldberg; Douglas C Cheung; Thenappan Chandrasekar; Zachary Klaassen; Christopher J D Wallis; Girish S Kulkarni; Rashid Sayyid; Andrew Evans; Mehdi Masoomian; Bharati Bapat; Theodorus van der Kwast; Robert J Hamilton; Alexandre Zlotta; Neil Fleshner
Journal:  Can Urol Assoc J       Date:  2019-01-21       Impact factor: 1.862

3.  Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

Authors:  Joaquim Bellmunt; Hans von der Maase; Graham M Mead; Iwona Skoneczna; Maria De Santis; Gedske Daugaard; Andreas Boehle; Christine Chevreau; Luis Paz-Ares; Leslie R Laufman; Eric Winquist; Derek Raghavan; Sandrine Marreaud; Sandra Collette; Richard Sylvester; Ronald de Wit
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

4.  Influence of preoperative hydronephrosis and ureteral orifice involvement in the survival of patients undergoing radical cystectomy: A retrospective comparative study.

Authors:  Ertuğrul Şefik; Serdar Çelik; Bülent Günlüsoy; İsmail Basmacı; Serkan Yarımoğlu; İbrahim Halil Bozkurt; Tansu Değirmenci; Çetin Dinçel
Journal:  Turk J Urol       Date:  2019-04-03

5.  Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population-based analysis (2004-2012).

Authors:  Meera R Chappidi; Max Kates; Michael H Johnson; Noah M Hahn; Trinity J Bivalacqua; Phillip M Pierorazio
Journal:  Urol Oncol       Date:  2016-07-27       Impact factor: 3.498

6.  The impact of tumor size on outcomes in patients with upper urinary tract urothelial carcinoma.

Authors:  Dragica Milenkovic-Petronic; Bogomir Milojevic; Milan Djokic; Sandra Sipetic-Grujicic; Isidora Grozdic Milojevic; Uros Bumbasirevic; Zoran Dzamic
Journal:  Int Urol Nephrol       Date:  2013-09-21       Impact factor: 2.370

7.  Preoperative hydronephrosis and diabetes mellitus predict poor prognosis in upper urinary tract urothelial carcinoma.

Authors:  Insang Hwang; Seung Il Jung; Deok-Hyun Nam; Eu Chang Hwang; Taek Won Kang; Dong Deuk Kwon; Soo Bang Ryu
Journal:  Can Urol Assoc J       Date:  2013 Mar-Apr       Impact factor: 1.862

8.  Preoperative risk stratification for cancer-specific survival of patients with upper urinary tract urothelial carcinoma treated by nephroureterectomy.

Authors:  Kazutoshi Fujita; Motohide Uemura; Yoshiyuki Yamamoto; Go Tanigawa; Wataru Nakata; Mototaka Sato; Akira Nagahara; Hiroshi Kiuchi; Yasutomo Nakai; Kiyomi Matsumiya; Seiji Yamaguchi; Norio Nonomura
Journal:  Int J Clin Oncol       Date:  2014-04-18       Impact factor: 3.402

Review 9.  Optimal treatment for metastatic bladder cancer.

Authors:  Estrella M Carballido; Jonathan E Rosenberg
Journal:  Curr Oncol Rep       Date:  2014-09       Impact factor: 5.075

10.  Analysis of the clinicopathological characteristics of patients with upper urinary tract transitional cell carcinoma.

Authors:  Claudio B Murta; Alberto A Antunes; Marcos F Dall'Oglio; Alcides Mosconi; Kátia R Leite; Miguel Srougi
Journal:  Clinics (Sao Paulo)       Date:  2008-04       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.